Research location
Geneva
Canton of Geneva, Switzerland
Advertisement
Research activity in Geneva
Canton of Geneva, SwitzerlandCureCurrent currently publishes aggregate city-level research activity for this location: 85 trials and 87 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Geneva
85 linked trials · page 1 of 2Tractography-Guided Nerve-Sparing in Prostate CancerNCT07847385 · 2026-09-01 · 1 site observation
RECRUITING
SPECTRA: Intraoperative Hyperspectral Imaging for Prostate CancerNCT07826858 · 2026-08-01 · 1 site observation
RECRUITING
A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung CancerNCT07365241 · 2026-07-02 · 1 site observation
RECRUITING
Investigation of Gastric Emptying by Gastric Ultrasonography in Diabetic Patients Treated With GLP-1 ReceptorsNCT07506356 · 2026-04-01 · 1 site observation
RECRUITING
Hypnosis on Breathlessness Mastery in Patients With Persistent DyspneaNCT07173348 · 2026-04-01 · 1 site observation
RECRUITING
Breast Cancer-Related Approach for Increasing Cervical Cancer ScreeningNCT07171658 · 2025-10-07 · 1 site observation
RECRUITING
Breathlessness Patterns in Patients With Cancer, COPD and Heart Failure: an fMRI Feasibility StudyNCT07319039 · 2025-08-26 · 1 site observation
RECRUITING
Can Pre-operative Lean Mass Predict Weight Loss After Roux-en-Y Gastric Bypass?NCT07565051 · 2025-08-18 · 1 site observation
RECRUITING
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)NCT06925737 · 2025-05-13 · 1 site observation
RECRUITING
Time-Restricted Eating in Menopause and HOrmone-sensitive Breast Cancers (TREMHO)NCT06855784 · 2025-04-30 · 1 site observation
RECRUITING
Improvement in Breast Skin Sensibility After Breast Reconstruction: a Comparison of 3 Surgical TechniquesNCT06930378 · 2025-04-01 · 1 site observation
RECRUITING
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)NCT06760819 · 2025-02-13 · 1 site observation
RECRUITING
Incremental Diagnostic Value of Tau-PET With [18F]RO948 vs Amyloid-PET in Patients With Cognitive ImpairmentNCT06618872 · 2024-12-03 · 1 site observation
RECRUITING
Beta-Cell - Liver Interactions in Situations of Modified Beta-Cell FunctionNCT06682481 · 2024-11-22 · 1 site observation
RECRUITING
Investigating aCute heArt failuRe Decongestion Guided by Lung UltraSonographyNCT06465498 · 2024-10-22 · 2 site observations
RECRUITING
Atrial Fibrillation Ablation Versus Atrioventricular Nodal Ablation with Conduction System Pacing in Heart FailureNCT06207383 · 2024-10-01 · 1 site observation
RECRUITING
Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)NCT06469944 · 2024-09-20 · 1 site observation
RECRUITING
Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)NCT06445972 · 2024-08-07 · 1 site observation
RECRUITING
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)NCT06393374 · 2024-06-24 · 1 site observation
RECRUITING
EMPATHY NSCLC: European Registry for Plasma-Based Molecular Profiling in Advanced NSCLC PatientsNCT07096258 · 2024-06-01 · 1 site observation
RECRUITING
OBPM_Meds2023: Multicentric Prospective Clinical Study to Evaluate the Aktiia Optical Blood Pressure Monitoring (OBPM) Device Compared to Standard Home Blood Pressure Monitoring (HBPM) in Hypertensive Patients When Blood Pressure Lowering Medications IntakeNCT05780710 · 2023-06-29 · 1 site observation
RECRUITING
A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)NCT05319730 · 2023-05-16 · 1 site observation
RECRUITING
Anhydroglucitol in Children With Type 1 DiabetesNCT05594706 · 2023-01-27 · 1 site observation
RECRUITING
Understanding Brain Mechanisms Involved in Autobiographical MemoryNCT05710549 · 2022-04-25 · 1 site observation
RECRUITING
Cascade Genetic Testing for Hereditary Breast/Ovarian Cancer and Lynch Syndrome in SwitzerlandNCT03124212 · 2017-04-01 · 1 site observation
RECRUITING
Swiss Multiple Sclerosis Cohort-StudyNCT02433028 · 2012-06-01 · 1 site observation
RECRUITING
FAPI PET Imaging - An Exploratory StudyNCT07705074 · 2026-08-01 · 1 site observation
NOT_YET_RECRUITING
Effect of Pre-operative Exercise Training on Cardiorespiratory Fitness in Patients With Locally Advanced Non-small Cell Lung Cancer Undergoing Induction Chemo-immunotherapy Followed by Surgery - a Randomized Controlled StudyNCT07479407 · 2026-04-01 · 1 site observation
NOT_YET_RECRUITING
Genetic Hallmarks of Patients With Congenital Portosystemic Shunts and Portopulmonary HypertensionNCT07314814 · 2026-02-01 · 1 site observation
NOT_YET_RECRUITING
Underweight, Overweight, and Linear Growth of Childhood Cancer Patients - the Growth StudyNCT07750444 · 2025-10-01 · 1 site observation
ACTIVE_NOT_RECRUITING
Supporting Patients Starting New Medicines: Evaluating the myCare Start Service in SwitzerlandNCT07036471 · 2025-06-01 · 1 site observation
NOT_YET_RECRUITING
Brief Title: INTROSPECT: Intraoperative PSMA PET/CT Imaging During Radical ProstatectomyNCT07829068 · 2025-05-30 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of Islatravir (ISL) and Ulonivirine (ULO) Once Weekly (QW) in Virologically Suppressed Adults With Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8591B-060)NCT06891066 · 2025-04-14 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary FibrosisNCT06025578 · 2023-10-25 · 1 site observation
ACTIVE_NOT_RECRUITING
Study of MK-0472 in Participants With Advanced/Metastatic Solid Tumors (MK-0472-001)NCT05853367 · 2023-07-06 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of Doravirine/Islatravir (DOR/ISL, MK-8591A) for the Treatment of Human Immunodeficiency Virus 1 (HIV-1) Infection in Participants Who Previously Received DOR/ISL (MK-8591A-054)NCT05766501 · 2023-03-17 · 1 site observation
ACTIVE_NOT_RECRUITING
A Switch to Doravirine/Islatravir (DOR/ISL) in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are Virologically Suppressed on Antiretroviral Therapy (ART) (MK-8591A-051)NCT05631093 · 2023-02-20 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of Adjuvant Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab for Resected High-Risk Melanoma in Participants With High-Risk Stage II-IV Melanoma (MK-7684A-010/KEYVIBE-010)NCT05665595 · 2023-01-19 · 1 site observation
TERMINATED
A Study of MK-6598 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Advanced Solid Tumors (MK-6598-001)NCT05594043 · 2022-12-21 · 1 site observation
COMPLETED
Immune Response of Shingrix Vaccine in People Living With HIV (> 50 y.o.) Compared to Age-matched ControlsNCT05575830 · 2022-12-14 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of Combination Therapies With or Without Pembrolizumab (MK-3475) and/or Chemotherapy in Participants With Advanced Esophageal Cancer (MK-3475-06A)NCT05342636 · 2022-07-27 · 1 site observation
COMPLETED
The DIALOGUE Study: Swiss-Korean Billateral CollaborationNCT04214210 · 2022-04-15 · 1 site observation
COMPLETED
Substudy 02D: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Melanoma Brain Metastasis (MK-3475-02D/KEYMAKER-U02)NCT04700072 · 2021-05-03 · 1 site observation
COMPLETED
Safety and Efficacy of Coformulated Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib (E7080/MK-7902) in Advanced Hepatocellular Carcinoma (MK-1308A-004)NCT04740307 · 2021-03-16 · 1 site observation
COMPLETED
Dose Ranging, Switch Study of Islatravir (MK-8591) and Ulonivirine (MK-8507) Once-Weekly in Virologically-Suppressed Adults With Human Immunodeficiency Virus Type 1 (HIV-1) [MK-8591-013]NCT04564547 · 2021-03-09 · 1 site observation
COMPLETED
Treatment Of Atrial Fibrillation In Preserved Cardiac Function Heart FailureNCT04160000 · 2020-07-26 · 1 site observation
UNKNOWN
Substudy 02B: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With First Line (1L) Advanced Melanoma (MK-3475-02B/KEYMAKER-U02)NCT04305054 · 2020-07-01 · 1 site observation
COMPLETED
Substudy 02A: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents in Participants With Programmed Cell-death 1 (PD-1) Refractory Melanoma (MK-3475-02A/KEYMAKER-U02)NCT04305041 · 2020-06-26 · 1 site observation
COMPLETED
Substudy 02C: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Stage III Melanoma Who Are Candidates for Neoadjuvant Therapy (MK-3475-02C/KEYMAKER-U02)NCT04303169 · 2020-06-26 · 1 site observation
COMPLETED
Safety and Efficacy of a Switch to Doravirine/Islatravir in Participants With HIV-1 (MK-8591A-017)NCT04223778 · 2020-02-18 · 1 site observation
COMPLETED
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.